Navigation Links
Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/13/2008

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 at approximately 3:10 p.m. Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at http://www.gen-probe.com. The webcast will be available for 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2008, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Paula Izidoro

Investor Relations

858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
2. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
3. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
4. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
5. Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference
8. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
9. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
10. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
11. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):